Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
LGVN
LGVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGVN News
Longeveron Raises $15M to Advance Laromestrocel Therapy
5h ago
Benzinga
Avaí Bio Advances Cell Therapy Production Milestone
Mar 03 2026
PRnewswire
Avaí Bio Advances α-Klotho Cell Production Milestone
Mar 03 2026
Newsfilter
Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy
Feb 25 2026
stocktwits
Longeveron Reports Positive Phase 2b Clinical Trial Results
Feb 25 2026
Newsfilter
Longeveron Appoints New CEO Stephen H. Willard
Feb 13 2026
seekingalpha
Longeveron Appoints New CEO to Drive Growth
Feb 13 2026
Newsfilter
Pediatric Priority Review Voucher Program Reauthorized
Feb 05 2026
Newsfilter
Longeveron Secures Japanese Patent for Stem Cell Therapy Assays
Jan 29 2026
Newsfilter
Longeveron Joins JPM Healthcare Week to Focus on Alzheimer's Disease
Dec 29 2025
Globenewswire
Longeveron Joins Alzheimer's Health Moonshot Initiative During JPM Healthcare Week
Dec 29 2025
Newsfilter
Longeveron Secures Patent for Treating Female Sexual Dysfunction
Dec 17 2025
Newsfilter
Longeveron Secures Patent for Treating Female Sexual Dysfunction
Dec 17 2025
Globenewswire
Longeveron Executives to Speak at CVCT Forum on Cell Therapy Innovations
Dec 03 2025
Newsfilter
Longeveron Executives to Speak at Global CVCT Forum on Cell Therapy Innovations
Dec 03 2025
Globenewswire
Longeveron Secures Canadian Patent for Aging-Related Frailty Treatment
Dec 02 2025
Newsfilter
Show More News
